AptarGroup, Inc.'s SEC filings document operating results, governance matters and capital-structure activity for a NYSE-listed maker of drug delivery and consumer-product dispensing technologies. Form 8-K reports furnish quarterly and annual results, segment commentary for Pharma, Beauty and Closures, shareholder returns and material events tied to the company's operations.
The filing record also includes proxy materials and annual meeting vote results covering director elections, advisory compensation matters and stockholder voting items. Capital disclosures include common stock registered under the Exchange Act, shelf-registration activity and completed debt financing, including the 4.750% Senior Notes due 2031 issued under an indenture.
APTARGROUP, INC. Chief Human Resources Officer Shiela Vinczeller reported a small share disposition related to taxes. On the reported date, 168 shares of common stock were delivered at $145.72 per share to cover tax obligations. After this tax-withholding disposition, she directly owned 24,966 common shares.
APTARGROUP President and CEO Stephan B. Tanda reported a tax-related share disposition. On February 23, 2026, 987 shares of common stock were withheld at $145.72 per share to cover tax liability, leaving him with 203,999 directly owned shares and 3,127 shares held indirectly through a 401(k) trust.
APTARGROUP, INC. Segment President Gael Touya reported an open-market sale of company stock. On February 18, 2026, he sold 3,500 shares of common stock at a weighted average price of $141.3539 per share, executed in multiple trades between $141.2250 and $141.8050. After this transaction, he directly owned 27,963 shares of AptarGroup common stock.
Registrant filed a Form 144 proposing the sale of 3,500 common shares.
The filing lists an aggregate offering price of $494,738.65 and states shares outstanding were 64,379,735 as of 02/18/2026. The securities are described as restricted stock vesting under a registered plan with vesting entries including 485 (02/25/2022) and 1,417 (03/25/2022).
AptarGroup, Inc. executive share sale reported. Segment President Marc Prieur sold 2,000 shares of AptarGroup common stock on February 10, 2026 at a price of $137.81 per share. After this transaction, he beneficially owns 13,745 shares of AptarGroup common stock, held directly.
Morgan Stanley has disclosed a significant passive stake in AptarGroup, Inc. (ATR). As of 12/31/2025, Morgan Stanley reports beneficial ownership of 4,019,724 shares of AptarGroup common stock, representing 6.1% of the outstanding class.
The firm reports no sole voting or dispositive power. It has shared voting power over 3,688,486 shares and shared dispositive power over 3,885,398 shares. Morgan Stanley certifies that these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of AptarGroup. This filing is Amendment No. 10 to its Schedule 13G.
AptarGroup, Inc. shareholder has filed a Form 144 notice to sell 2,000 common shares. The planned sale is through UBS Switzerland AG on the NYSE, with an aggregate market value of $272,000 and 66,543,252 shares outstanding. The approximate sale date indicated is February 9, 2026.
The 2,000 common shares were acquired on March 23, 2024 via restricted stock units (RSUs) and performance stock units (PSUs) granted by AptarGroup, Inc., and paid in the form of these equity awards.
AptarGroup, Inc. is a global supplier of dosing, dispensing and protection technologies for pharmaceuticals, beauty, personal care, home care, food and beverage products. The company operates three segments: Pharma, Beauty and Closures.
In 2025, Pharma generated about 46% of net sales and 69% of adjusted EBITDA (excluding non-allocated corporate costs), supplying nasal spray pumps, inhaler valves, injectable elastomer components, active material science solutions and digital health tools. Beauty contributed roughly 35% of net sales with pumps, airless systems and valves for fragrance, skincare, cosmetics and personal care. Closures represented about 19% of net sales, focusing on dispensing closures for food, beverage and personal care applications.
Aptar is geographically diversified, with 57 manufacturing facilities worldwide and approximately 14,000 employees, and no single customer exceeding 4% of 2025 net sales. The company emphasizes sustainability, including science-based emissions targets, recyclable and PCR-based packaging solutions, and multiple external recognitions for environmental and social performance. Recent portfolio moves include acquiring Sommaplast for $27 million, increasing ownership in BTY to 80% for about $29 million, and a 40% stake in Goldrain for about $99 million.
Key risks highlighted include macroeconomic weakness, geopolitical tensions and tariffs, supply chain and single‑source material dependence, cybersecurity threats, foreign currency volatility, labor relations, environmental and packaging regulations, tax changes, climate-related impacts and exposure to routine litigation and regulatory oversight.
AptarGroup reported solid 2025 growth with some margin pressure. Fourth quarter 2025 sales rose 14% to $962.7 million, but net income fell to $74.3 million and diluted EPS declined to $1.13 from $1.49 as mix and higher production costs weighed on profitability.
For full-year 2025, sales increased 5% to $3.78 billion and diluted EPS grew 7% to $5.89, while adjusted EPS slipped 1% to $5.74. Pharma, Beauty and Closures all delivered core sales growth, and adjusted EBITDA margin held at 21.6%. The company generated $570 million in operating cash flow and $302.9 million in free cash flow, ended the year with $410 million in cash and short-term investments and net debt of $1.07 billion, and reported a leverage ratio of 1.38. Aptar returned $486 million to shareholders via dividends and buybacks in 2025, including repurchasing 1.5 million shares for $175 million in the fourth quarter, and its board approved a new authorization to repurchase up to $600 million of common stock. The company guided first quarter 2026 adjusted EPS to $1.13–$1.21 and plans 2026 capital investments of $260–$280 million.